|
2.11 Etiologie - Alimentation
|
|
|
|
3.1 Tabac
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
Evaluation of a Single Metastasis in Metastatic Prostate Cancer [ESMO]
|
|
|
|
|
|
By
analysing an intraindividual molecular diversity of metastatic prostate
cancer, the researchers discovered that although exceptions exist,
evaluation of a single metastasis provides a reasonable assessment of
the major oncogenic driver alterations that are present in disseminated
tumours within an individual, and thus may be useful for selection of
treatments on the basis of predicted molecular vulnerabilities.
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
Recalibrating cancer clinical trials [National Cancer Institute]
|
|
|
|
|
|
The
results of CREATE-X have not yet been published in a peer-reviewed
journal. But, given the impressive initial results with capecitabine in
this patient population, NCI and the trial leaders from ECOG-ACRIN
decided that the best course of action was to temporarily halt the
EA1131 trial to allow for a careful review of the available data from
CREATE-X.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
|
Gilead Cancer Business Loses Top Exec Prior to Study Halts [TheStreet]
|
|
|
|
|
|
"Strategically,
what we want to do, instead, is to ask the question: What is it about
the 70% to 80% of people that don't have a response to anti-PD1
therapy," said Bischofberger. "We're absolutely very interested in
immuno-oncology but only if it is a truly differentiated compound from
what is on the market or in late-stage clinical studies."
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
NICE says 'no' to talimogene laherparepvec in melanoma [European Pharmaceutical Review]
|
|
|
|
|
|
“However,
the committee concluded that there was not enough evidence to be able
to say whether talimogene laherparepvec is as clinically effective as
other drugs used to treat advanced melanoma. Given the uncertainty about
its effect on overall survival compared with these drugs it was not
possible to recommend talimogene laherparepvec as a cost-effective use
of NHS resources.”
|
|
|
|
|
|
|
|
UK cost agency rejects Amgen's virus-based cancer drug [Reuters]
|
|
|
|
|
|
The
National Institute for Health and Care Excellence said on Wednesday
there was not enough evidence to be able to say whether Imlygic, also
known as talimogene laherparepvec or "T-Vec", was as clinically
effective as other drugs for the deadly skin cancer.
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10 Politiques
|
|
|
|
|
6.4 Médico-éco
|
|
|
Obama Plans To Use Value Pricing To Rein In Medicare Drug Costs [NPR]
|
|
|
|
|
|
The
results could lead to a profound shift in how the Centers for Medicare
& Medicaid Services spends $20 billion a year for drugs under Part
B, which are those given through doctors' offices and hospital
outpatient centers. Many cancer treatments are provided that way, as are
some treatments for rheumatoid arthritis, macular degeneration and
other medical conditions.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|